Company intelligence / Profile preview

Beijing Zhong Sheng Heng Yi Pharmaceutical Technology

Beijing, China

Ownership: Private
Development stage: Other

Overview

The company has completed a Phase 1 study and has conducted/ongoing Phase 2 trials for a recombinant norovirus bivalent (GI.1/GII.4) vaccine and has an ongoing Phase 1/2 clinical program for a recombinant SARS-CoV-2 (COVID-19) vaccine, both showing advancement to mid-stage clinical testing with focus on safety and immunogenicity in pediatric and adult populations.

Therapeutic areas: Infectious Diseases
Modalities: VaccineRecombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Beijing Zhong Sheng Heng Yi Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Zhong Sheng Heng Yi Pharmaceutical Technology.

Explore the full profile